PDSB

Business Context and Reporting Period

PDS Biotechnology Corp (PDSB) is a clinical-stage biotechnology company focused on developing PDS0301, a tumor-targeted IL-12 immunocytokine. The company also maintains the Versamune® platform (PDS0101) and Infectimune® platform. This Form 10-Q covers the quarterly period ended June 30, 2026. The company has no commercially approved products and has incurred net losses since inception.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by 15% ($1.13 million) for the three months ended June 30, 2026, compared to the same period in 2025. This was driven by a 22% reduction in R&D expenses and a 5% reduction in G&A expenses.
• Net Loss: Net loss increased slightly by 3% ($0.32 million) for the three months ended June 30, 2026, primarily due to higher net interest expenses ($3.25 million vs. $1.81 million in the prior year quarter).
• Liquidity: Cash and cash equivalents declined significantly from $26.71 million at December 31, 2025, to $5.60 million at June 30, 2026, a decrease of approximately $21.1 million.
• Debt Structure: The company redeemed $22.2 million in senior secured convertible debentures in June 2026. Concurrently, it issued a new $6.0 million promissory note in June 2026.
• Equity: The company moved from positive stockholders' equity ($9.25 million) at year-end 2025 to negative equity ($(3.58) million) by June 30, 2026.

Guidance, Outlook, and Risks

• Strategic Refocus: In August 2026, the company announced a strategic refocus to prioritize PDS0301. Consequently, it discontinued the VERSATILE-003 Phase 3 clinical trial for PDS0101 and ceased internal investment in that program, seeking external partnerships instead.
• Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least 12 months from the filing date due to recurring losses, negative cash flows, and limited cash resources ($5.6 million).
• Financing Needs: The company expects to require substantial additional capital to fund operations and clinical trials. It plans to raise funds through equity offerings, debt financing, or strategic collaborations. Failure to secure financing could force the company to delay or terminate development programs.
• Nasdaq Compliance: The company received a deficiency letter from Nasdaq on July 30, 2026, regarding its stock price falling below the $1.00 minimum bid price requirement. Failure to regain compliance within 180 days could result in delisting.
• Debt Covenants: The new $6.0 million promissory note includes covenants that restrict additional indebtedness and liens. It also contains a "Special Amortization Event" clause requiring accelerated repayment if the company fails to cure the Nasdaq minimum bid price requirement within 75 days.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $5.6 million cash balance against the burn rate and upcoming clinical trial costs for PDS0301.
• Debt Obligations: Review the terms of the $6.0 million promissory note, specifically the acceleration triggers related to Nasdaq listing compliance.
• Nasdaq Status: Monitor the company's progress in regaining compliance with the $1.00 minimum bid price rule to avoid delisting.
• Partnership Progress: Assess the status of potential strategic partnerships for the PDS0101 program following the discontinuation of the Phase 3 trial.
• Dilution Risk: Evaluate the potential dilution from future equity financings or the exercise of outstanding warrants (approx. 16.7 million shares) and options (approx. 8.6 million shares).